Results of stereotactic radiotherapy for stage I non-small-cell lung cancer: is there a need for image guidance and highly sophisticated devices?

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Bradley J, Graham MV, Winter K et al. Toxicity and outcome results of RTOG 9311: a Phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys.61(2),318–328 (2005).
  MedlineGoogle Scholar
• 2  Arimoto T, Usubuchi H, Matsuzawa T et al. Small volume multiple non-coplanar arc radiotherapy for tumors of the lung, head and neck and the abdominopelvic region. In: CARS 98 Computer Assisted Radiology and Surgery. Lemke H, Vannier MW, Inamura K, Graman AG (Eds). Elsevier Press, The Netherlands, 257–261 (1998).
  Google Scholar
• 3  Baumann P, Nyman J, Lax I et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol.45,787–795 (2006).
  MedlineGoogle Scholar
• 4  Baumann P, Nyman J, Hoyer M et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – a first report of toxicity related to COPD/CVD in a non-randomized prospective Phase II study. Radiother. Oncol.88,359–367 (2008).
  MedlineGoogle Scholar
• 5  Beitler J, Badine EA, El-Sayah D et al. Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. Int. J. Radiat. Oncol. Biol. Phys.65,100–106 (2006).
  MedlineGoogle Scholar
• 6  Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol.34,861–870 (1995).
  Medline CASGoogle Scholar
• 7  Brown WT, Wu X, Fayad F et al. Application of robotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent. Clin. Oncol.21,623–631 (2009).
  Medline CASGoogle Scholar
• 8  Chen VJ, Oermann E, Vahdat S et al. Cyberknife with tumor tracking: an effective treatment for high-risk surgical patients with stage I non-small cell lung cancer. Front. Oncol.2,1–5 (2012).
  CASGoogle Scholar
• 9  Collins BT, Vahdat S, Erickson K et al. Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J. Hematol. Oncol.2,1–9 (2009).
  MedlineGoogle Scholar
• 10  Dunlap NE, Larner J, Read PW et al. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). Gen. Thorac. Surg.40,583–589 (2010).
  Google Scholar
• 11  Fritz P, Kraus HJ, Blaschke T et al. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer60,193–199 (2008).▪ Best clinical trial on radiosurgery, although it still reports lower control rates than with fractionated radiotherapy. Further dose escalation trials are needed.
  MedlineGoogle Scholar
• 12  Guckenberger M, Meyer J, Wilbert J et al. Intra-fractional uncertainties in cone-beam CT based image-guided radiotherapy of pulmonary tumors. Radiother. Oncol.83,57–64 (2007).
  MedlineGoogle Scholar
• 13  Hamamoto Y, Kataoka M, Yamashita M et al. Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors. Jpn J. Radiol.30(5),430–434 (2012).
  MedlineGoogle Scholar
• 14  Hara R, Itami J, Kondo T et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer106,1347–1352 (2006).
  MedlineGoogle Scholar
• 15  Hata M, Tokuuye K, Kagel K et al. Hypofractionated high-dose proton beam therapy for stage I non-small cell lung cancer: preliminary results of a Phase I/II clinical study. Int. J. Radiat. Oncol. Biol. Phys.68,786–793 (2007).
  MedlineGoogle Scholar
• 16  Hof H, Muenter M, Oetzel D et al. Stereotactic single-does radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC). Cancer110,148–155 (2007).
  MedlineGoogle Scholar
• 17  Joyner M, Salter BJ, Papanikolaou N, Fuss M. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol.45,802–807 (2006).
  MedlineGoogle Scholar
• 18  Lagerwaard F, Van Sornsen de Koste J et al. Multiple ‘slow’ CT scans for incorporating lung tumor mobility in radiotherapy planning. Int. J. Radiat. Oncol. Biol. Phys.51,932–937 (2001).
  Medline CASGoogle Scholar
• 19  Lagerwaard FJ, Haasbeek CJA, Smit EF et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.70,685–692 (2008).▪ Largest single-center trial using 4D CT for planning only, and no imaging in the treatment room.
  MedlineGoogle Scholar
• 20  Lee S, Choi EK, Park HJ et al. Stereotactic body frame based fractionated radiosurgery in the consecutive days for primary and metastatic tumor in the lung. Lung Cancer40,309–315 (2003).
  MedlineGoogle Scholar
• 21  McGarry RC, Papiez L, Williams M et al. Stereotactic body radiation therapy of early stage non-small cell lung cancer: Phase I study. Int. J. Radiat. Oncol. Biol. Phys.63,1010–1015 (2005).
  MedlineGoogle Scholar
• 22  Nagata Y, Negoro Y, Aoki T et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int. J. Radiat. Oncol. Biol. Phys.52,1041–1046 (2002).
  MedlineGoogle Scholar
• 23  Nagata Y, Negoro Y, Aoki T et al. Clinical outcomes of a Phase I/II study of 48Gy of stereotactic body radiation therapy in 4 fractions using a stereotactic body frame. Int. J. Radiat. Oncol. Biol. Phys.63,1427–1431 (2005).
  MedlineGoogle Scholar
• 24  Nuyttens J, van der Voort van Zyp NC, Praag J et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother. Oncol.102,383–387 (2012).
  MedlineGoogle Scholar
• 25  Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer – mature results for medically inoperable patients. Lung Cancer51,97–103 (2006).
  MedlineGoogle Scholar
• 26  Olsen JR, Robinson CG, El Naqa I et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.81,E299–E303 (2011).
  MedlineGoogle Scholar
• 27  Onimaru R, Shirato H, Shimizu S et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int. J. Radiat. Oncol. Biol. Phys.56,126–135 (2003).
  MedlineGoogle Scholar
• 28  Onimaru R, Fujino M, Yamazaki K et al. Steep-dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.70,374–381 (2008).
  Medline CASGoogle Scholar
• 29  Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J. Thorac. Oncol.7,S94–S100 (2007).▪ Largest trial of stereotactic radiation therapy (SBRT) on non-small-cell lung cancer stage I including simple techniques and pronouncing the value of functional status of the treated patients: higher control rates for operable patients.
  Google Scholar
• 30  Panettieri V, Wennberg B, Gagliardi G et al. SBRT of lung tumors: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems. Phys. Med. Biol.52,4265–4281 (2007).
  MedlineGoogle Scholar
• 31  Pennathur A, Luketich JD, Heron DE et al. Stereotactic radiosurgery for the treatment of stage I non-small cell lung cancer in high-risk patients. J. Thorac. Cardiovasc. Surg.137,597–604 (2009).
  MedlineGoogle Scholar
• 32  Salazar OM, Sandhu TS, Lattin PB et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Int. J. Radiat. Oncol. Biol. Phys.72,707–715 (2008).
  MedlineGoogle Scholar
• 33  Shirato H, Shimizu S, Tadashi S et al. Real time tumour tracking radiotherapy. Lancet353,1331–1332 (1999).
  Medline CASGoogle Scholar
• 34  Takeda T, Sanuki N, Kunieda E et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int. J. Radiat. Oncol. Biol. Phys.73,442–448 (2009).
  MedlineGoogle Scholar
• 35  Timmerman R, McGarry R, Yiannoutsos C et al. Excessive toxicity when treating central tumors in a Phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol.24,4833–4839 (2006).▪ Clear description of the limitations of high single fractions in SBRT for centralized lung cancer.
  MedlineGoogle Scholar
• 36  Timmerman R, Bastasch M, Saha D et al. Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front. Radiat. Ther. Oncol.40,352–365 (2007).
  MedlineGoogle Scholar
• 37  Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J. Thorac. Oncol.2,S101–S112 (2007).
  MedlineGoogle Scholar
• 38  Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA303,1070–1076 (2010).
  Medline CASGoogle Scholar
• 39  Uematsu M, Shioda A, Suda A et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small-cell lung cancer: a 5-year experience. Int. J. Radiat. Oncol. Biol. Phys.51,666–670 (2001).▪ Describes a simple but successful technique of SBRT.
  Medline CASGoogle Scholar
• 40  Wulf J, Haedinger U, Oppitz U et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int. J. Radiat. Oncol. Biol. Phys.60,186–196 (2004).
  MedlineGoogle Scholar
• 41  Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother. Oncol.77,83–87 (2005).
  MedlineGoogle Scholar
• 42  Xia T, Li H, Sun Q et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.66,117–125 (2006).
  MedlineGoogle Scholar
• 43  Zimmermann FB, Geinitz H, Schill S et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer48,107–114 (2005).
  MedlineGoogle Scholar
• 44  Zimmermann F, Wulf J, Lax I et al. Stereotactic body radiation therapy for early non-small cell lung cancer. Front. Radiat. Ther. Oncol.42,94–114 (2010).
  MedlineGoogle Scholar
• 45  Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superior located stage I non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.80,1015–1022 (2011).▪ Precise definition of the options and limitations of proton therapy aiming at small targets in the lung.
  MedlineGoogle Scholar
• 46  Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.70,847–852 (2008).▪ Radiobiological model to compare different fractionation schedules for SBRT even with very high single doses; can be used when starting SBRT with a new fractionation concept.
  MedlineGoogle Scholar
• 47  Crabtree TG, Kymes S, Gregory M et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. J. Thorac. Cardiovasc. Surg.143(2),428–436 (2012).
  MedlineGoogle Scholar
• 48  Nakayama H, Sugahara S, Tokita M et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the University of Tsukuba. Int. J. Radiat. Oncol. Biol. Phys.78,467–471 (2010).
  MedlineGoogle Scholar
• 49  Wennberg BM, Baumann P, Gagliardi G et al. NTCP modeling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncol.50,518–527 (2011).▪ Radiobiological model to compare different fractionation schedules for SBRT regarding toxicity of normal tissue; can be used when starting SBRT with a new fractionation concept.
  MedlineGoogle Scholar
• 50  Bongers EM, Dahele MR, Slotman BJ, Senan S. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superior located stage I non-small-cell lung cancer, in regards to Register et al.Int. J. Radiat. Oncol. Biol. Phys.82,492 (2012).
  MedlineGoogle Scholar
• 51  Solberg TD, Balter JM, Benedict SH et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: executive summary. Pract. Radiat. Oncol.2,2–9 (2012).
  MedlineGoogle Scholar
• 52  Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur. J. Radiol.79,147–154 (2011).
  MedlineGoogle Scholar
• 53  Van der Voort van Zyp NC, Prévost JB, Hoogeman MS et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother. Oncol.91,296–300 (2009).
  MedlineGoogle Scholar
• 54  Bernstein ED, Herbert SM, Hanna NH. Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer. Ann. Surg. Oncol.13,291–301 (2006).
  MedlineGoogle Scholar
• 55  Coleman MH, Bueno R. Role of adjuvant chemotherapy in NSCLC (stage I–III). Surg. Oncol. Clin. N. Am.20,757–767 (2011).
  MedlineGoogle Scholar
• 56  Koenig TR, Kunden RF, Erasmus JJ et al. Radiation injury of the lung after three-dimensional conformal radiotherapy. AJR Am. J. Roentgenol.178,1383–1388 (2002).
  MedlineGoogle Scholar
• 57  Aoki T, Nagata Y, Negoro Y et al. Evaluation of lung injury after three dimensional conformal stereotactic radiotherapy for solitary lung tumors. Radiology230,101–108 (2004).
  MedlineGoogle Scholar